Tolero Pharmaceuticals, Inc.
- Headquarters
- Lehi, UT
- Founded
- 2011
- Latest Form D
- $14.2M, Aug 2014
- Total capital
- $17.7M
- Federal grants
- $200K
- 1 award · 2012
- Private capital raised
- $17.5M
- 2 Form D · last Aug 2014
- 146 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 21
- 15 pending · first 2016
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$14.2M
- Federal grantHealth and Human S · N43 · Targeting Bmp Signaling With TP-0413$200K
- Private capital raisedForm D · SEC · 1st filing$3.3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
Researcher links verified by same-company patents and grants- David BearssResearcherExecutive Officer, DirectorLinked by 5 patents
- Dallin AndersonExecutive Officer, Director, PromoterNamed in SEC Form D filings
- David Bearss, Ph.D.Executive Officer, Director, PromoterNamed in SEC Form D filings
What it has protected
USPTO · 21 granted of 36- GrantedPKM2 Modulators And Methods For Their UseUSPTOUS 10,766,865
- GrantedJAK2 And ALK2 Inhibitors And Methods For Their UseUSPTOUS 10,752,594
- GrantedCombination Therapies For Treatment Of CancerUSPTOUS 10,682,356
Show all 36 patent records
- PKM2 Modulators And Methods For Their UseSep 8, 2020 · US 10,766,865Granted
- JAK2 And ALK2 Inhibitors And Methods For Their UseAug 25, 2020 · US 10,752,594Granted
- Combination Therapies For Treatment Of CancerJun 16, 2020 · US 10,682,356Granted
- Predicting Response To Alvocidib By Mitochondrial ProfilingApr 21, 2020 · US 10,624,880Granted
- Combination Therapies For Treatment Of CancerFeb 25, 2020 · US 10,568,887Granted
- Alvocidib Prodrugs Having Increased BioavailabilityFeb 18, 2020 · US 10,562,925Granted
- PKM2 Modulators And Methods For Their UseNov 12, 2019 · US 10,472,328Granted
- Profiling Peptides And Methods For Sensitivity ProfilingSep 24, 2019 · US 10,422,788Granted
- Substituted IMIDAZO[1,2-B]PYRIDAZINES As Protein Kinase InhibitorsAug 27, 2019 · US 10,392,392Granted
- Predicting Response To Alvocidib By Mitochondrial ProfilingJul 23, 2019 · US 10,357,488Granted
- Profiling Peptides And Methods For Sensitivity ProfilingApr 23, 2019 · US 10,267,787Granted
- Alvocidib Prodrugs Having Increased BioavailabilityApr 16, 2019 · US 10,259,835Granted
- PKM2 Modulators And Methods For Their UseFeb 19, 2019 · US 10,207,996Granted
- JAK2 And ALK2 Inhibitors And Methods For Their UseFeb 12, 2019 · US 10,202,356Granted
- Profiling Peptides And Methods For Sensitivity ProfilingNov 20, 2018 · US 10,132,797Granted
- Substituted IMIDAZO[1,2-B]PYRIDAZINES As Protein Kinase InhibitorsAug 14, 2018 · US 10,047,093Granted
- Predicting Response To Alvocidib By Mitochondrial ProfilingFeb 27, 2018 · US 9,901,574Granted
- Alvocidib Prodrugs Having Increased BioavailabilitySep 12, 2017 · US 9,758,539Granted
- Multiple Kinase Pathway InhibitorsJul 25, 2017 · US 9,714,247Granted
- Multiple Kinase Pathway InhibitorsNov 15, 2016 · US 9,493,454Granted
- PKM2 Modulators And Methods For Their UseJul 19, 2016 · US 9,394,257Granted
- Heterocyclic Protein Kinase InhibitorsApplication PCTUS2012047685Pending
- Materials And Methods For Treating CancerApplication 62753712Pending
- PKM2 Activators In Combination With Reactive Oxygen Species For Treatment Of CancerApplication PCTUS2018055668Pending
- Compositions And Methods For Treating Cancers That Are Insensitive To BCL-2 Inhibitors Using MCL-1 InhibitorsApplication PCTUS2018050767Pending
- Materials And Methods For Treating CancerApplication 62653376Pending
- Profiling Peptides And Methods For Sensitivity ProfilingApplication PCTUS2017067430Pending
- Alvocidib Prodrugs And Their Use As Protein Kinase InhibitorsApplication PCTUS2017062408Pending
- Alvocidib Prodrugs Having Increased BioavailabilityApplication PCTUS2016033099Pending
- Predicting Response To Alvocidib By Mitochondrial ProfilingApplication PCTUS2016028443Pending
- Targeting Pim Kinases In Combination With Btk InhibitionApplication PCTUS2016025496Pending
- Methods To Target Transcriptional Control At Super-enhancer RegionsApplication PCTUS2015059566Pending
- JAK2 And ALK2 Inhibitors And Methods For Their UseApplication PCTUS2014026595Pending
- PKM2 Modulators And Methods For Their UseApplication PCTUS2013065296Pending
- Multiple Kinase Pathway InhibitorsApplication PCTUS2013061548Pending
- Treatment Of CancerApplication PCTUS2020041189Pending
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .